热门资讯> 正文
Dianthus Therapeutics报告FY结果
2024-03-22 05:16
- Dianthus Therapeutics press release (NASDAQ:DNTH): Net loss for the year ended December 31, 2023 was $43.6 million or $8.45 net loss per share (basic and diluted) compared to $28.5 million or $32.57 net loss for the year ended December 31, 2022.
- Research and development (R&D) expenses for the year ended December 31, 2023 were $32.8 million, inclusive of $0.9 million of stock-based compensation, compared to $29.4 million for the year ended December 31, 2022, which included $0.4 million of stock-based compensation.
- $389 million of pro forma cash includes cash, cash equivalents and short-term investments as of December 31, 2023
More on Dianthus Therapeutics
- Stifel starts Dianthus at buy, cites market potential of lead drug
- Historical earnings data for Magenta Therapeutics
- Financial information for Magenta Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
